News & Publications - Page 2 of 8

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market

  • KemPharm Announces 1-for-16 Reverse Stock Split

  • KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder

  • KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA

  • REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event

  • KemPharm Provides Update on Development Pipeline

  • KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event

  • KemPharm Reports Third Quarter 2020 Financial Results

  • KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call

  • KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting

  • KemPharm and Corium Expand Relationship with New Consultation Services Agreement

  • KemPharm Files Preliminary Proxy for Special Meeting of Stockholders